Wolverine Stack - does BPC-157 + TB-500 actually work together?
Wolverine Stack is the community name for using BPC-157 and TB-500 together. The idea is that they complement each other: BPC-157 works locally to build new blood vessels and bring fibroblasts to an injury site, and TB-500 works systemically by regulating actin (a core structural protein in cells) and moving healing cells around the body. The honest part: there are no peer-reviewed human randomized trials on this combination. Both peptides have animal data and Dr. William Seeds' clinical experience. If you use this stack, know what you're basing it on: clinical experience and animal data, not human trial endpoints.
- BPC-157 mechanism (preclinical): VEGFR2 activation drives new blood vessel formation; FAK-paxillin pathway drives fibroblast migration into injury sites; GH receptor upregulation on tendon fibroblasts amplifies healing
- BPC-157: mostly studied in rat and rodent models; no published human RCTs; target tissues include tendons, ligaments, gut, nervous system
- TB-500 (Thymosin Beta-4 fragment) mechanism (preclinical): regulates actin via the LKKTETQ actin-binding domain; promotes migration of keratinocytes, endothelial cells, and progenitor cells (2 to 3 fold)
- TB-500: angiogenesis effects; also studied in cardiac repair models; target tissues include muscle, skin, heart, connective tissue
- Seeds Protocol dosing reference: BPC-157 250 to 500 mcg per injection; TB-500 5 to 10 mg per week
- No human RCTs exist for the combination
Your guided peptide companion.
PRTCL walks beginners through their first peptide with confidence - guided reconstitution, dose calculation, vial tracking, and answers to questions like this one. Built for first-timers, useful for everyone.
- · Guided walkthrough for your first dose
- · Dose calculator that does the math for you
- · Vial inventory and dose log tracking
- · Library of physician-vetted protocols
Free to start. Sign in if you already have an account.